Loading...
•
Jun 30, 2023
Johnson & Johnson Q2 2023 Earnings Report
Johnson & Johnson reported a robust second-quarter performance, driven by pharmaceutical and MedTech innovation, with sales growth and EPS increase.
Key Takeaways
Johnson & Johnson reported a strong second quarter with sales growth of 6.3% to $25.5 billion and EPS of $1.96, increasing by 8.9%. The company is increasing its full-year guidance for adjusted operational sales and adjusted operational EPS, and plans to split off Kenvue shares through an exchange offer.
Second-Quarter reported sales growth of 6.3% to $25.5 Billion.
Earnings per share (EPS) of $1.96 increasing 8.9%.
Adjusted EPS of $2.80 increasing by 8.1%.
Company is increasing 2023 full-year guidance midpoints for adjusted operational sales excluding COVID-19 Vaccine and adjusted operational EPS.
Johnson & Johnson
Johnson & Johnson
Forward Guidance
Johnson & Johnson is increasing 2023 full-year guidance midpoints for adjusted operational sales excluding COVID-19 Vaccine and adjusted operational EPS.
Positive Outlook
- Adjusted Operational Sales Change vs. Prior Year Mid-point: 6.0% – 7.0% / 6.5%
- Operational Sales Change vs. Prior Year Mid-point: 7.0% – 8.0% / 7.5%
- Estimated Reported Sales Change vs. Prior Year Mid-point: 6.5% – 7.5% / 7.0%
- Adjusted Operational EPS (Diluted) Change vs. Prior Year Mid-point: $10.60 – $10.70 / $10.65
- Adjusted EPS (Diluted) Change vs. Prior Year Mid-point: $10.70 – $10.80 / $10.75